Skip to main content

Advertisement

Table 1 Baseline characteristics of patients with prostate cancer according to Vimentin CTC status

From: Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

Characteristic Vimentin CTC-negative patients (no vimentin + ve CTCs) (%) Vimentin CTC-positive patients (≥1 vimentin + ve CTC) (%)
Total patient numbers 63 30
Age, years
 Median 76 72
 Range 48–93 53–86
Number of metastasic sites
 1 26/63 (41.3) 11/30 (36.7)
 2 21/63 (33.3) 9/30 (30)
 3+ 15/63 (23.8) 10/30 (33.3)
 Not stated 1/63 (1.6) 0/30 (0)
Metastasic sites   
 Lymph Nodes alone 3/63 (4.8) 1/30 (3.3)
 Bone alone 24/63 (38.1) 10/30 (33.3)
 Bone and lymph nodes 17/63 (27) 6/30 (20)
 Visceral/multiple sites 19/63 (30.2) 13/30 (43.3)
Treatment at time of 1st CTC specimen
 Cabazitaxel 7/63 (11.1) 7/30 (23.3)
 Docetaxel 7/63 (11.1) 3/30 (10)
 Abiraterone 26/63 (41.3) 11/30 (36.7)
 Enzalutamide 5/63 (7.9) 2/30 (6.7)
 Radium 223 2/63 (3.2) 2/30 (6.7)
 Others/Not Stated 16/63 (25.4) 5/30 (16.7)
Line of treatment at time of 1st CTC specimen
 1 10/63 (15.9) 4/30 (13.3)
 2 17/63 (27) 8/30 (26.7)
 3+ 14/63 (22.2) 12/30 (40)
 Not stated 22/63 (34.9) 6/30 (20)
Previous treatments
 Primary surgery 10/63 (15.9) 7/30 (23.3)
 Primary radiotherapy 27/63 (42.9) 12/30 (40)
 Docetaxel 42/63 (66.7) 23/30 (76.7)
 Enzalutamide 2/63 (3.2) 4/30 (13.3)
 Cabazitaxel 10/63 (15.9) 7/30 (23.3)
 Abiraterone 21/63 (33.3) 12/30 (40)
Total CTC levels at baseline
 Mean 98.8 492.6
 Range 0–1185 1–4310